Complex Partial Seizures Treatment & Management
- Author: Elizabeth Carroll, DO; Chief Editor: Selim R Benbadis, MD more...
Treatment of complex partial seizures may involve pharmacologic therapy and, in certain cases, epilepsy surgery.[8, 9, 10, 11, 12, 13, 14, 15, 16, 17] Special considerations apply to women with childbearing potential.
There is no clear answer to the question of whether or not to treat after a single seizure. The risk of recurrent seizures is unchanged whether antiepileptic drugs are initiated after the first seizure or after the second. Attention to electroencephalographic (EEG) abnormalities, in addition to discussion with the patient and family, should be part of the decision-making process. In contrast, treatment with antiepileptic medication should always be initiated once a diagnosis of epilepsy is made.
All current antiepileptic drugs (AEDs), with the exception of ethosuximide, can be used in the treatment of complex partial seizures. The choice of an AED should be guided by certain general principles. The best-tolerated AED should be selected for the patient on the basis of side effects and drug interactions. Monotherapy is always initially preferred over polytherapy for treating seizures. High dosages of a single agent may be required to achieve seizure control before adding a second agent.
Treatment side effects
Side effects are common with all antiepileptic drugs. All AEDs are central nervous system (CNS) depressants and therefore may cause sedation, dizziness, and changes in cognition. This side effect is more common in older AEDs. Certain medications may offer favorable side effects (eg, topiramate and weight loss), whereas other medications may be chosen solely on the basis of their route of excretion (eg, levetiracetam and renal excretion). Some side effects may treat comorbidities (eg, gabapentin and certain pain syndromes).
Certain AEDs have specific toxicities (eg, hepatic failure or bone marrow suppression) that necessitate periodic blood monitoring. Patients should also be educated about how to recognize the signs of a severe adverse drug reaction.
AED therapy can be continued in the face of mild elevations of transaminase levels and mild depressions of blood cell counts because these findings do not indicate pending hepatic failure or aplastic anemia.
Considerations in women
Women of childbearing age should be educated regarding the drug interactions between AEDs and contraceptive therapy. Women who become pregnant and have a history of seizures should be continued on current antiepileptic drug therapy that controls seizures and not switched to a secondary agent simply because of pregnancy.
Teratogenicity is possible with all AEDs. Most have the potential to cause minor anomalies (eg, fetal anticonvulsant syndrome). Major anomalies (eg, cardiac defects, cleft lip and palate, microcephaly, developmental delay, and neural tube defects) are more common with valproate therapy, especially at high dosages. AEDs impair folic acid metabolism, increasing the risk of NTDs, requiring initiation of folic acid supplementation for all women of childbearing age at a minimum dose of 0.4 mg/day; however, higher doses between 2-5 mg/day are encouraged.
Clinicians should document in writing that they have advised every woman of childbearing potential of the risks and benefits of anticonvulsant therapy, including the increased risk of congenital malformations.[28, 29, 30, 31] Patients should be initiated on folic acid supplementation. Clinicians should also document they have advised women of childbearing age on the risk of oral contraceptive failure that may occur with hepatic enzyme–inducing anticonvulsants.
For more information, see Women's Health and Epilepsy.
Long-term anticonvulsant therapy with hepatic enzyme-inducing anticonvulsants also increases the risk for osteoporosis. Patients should undergo bone-density measurements every 2 years.
Anticonvulsant drug-level monitoring may be needed. Consider drug-level monitoring when noncompliance is suspected, in patients at high risk for life-threatening adverse drug reactions, or in patients with mental impairments that limit their ability to communicate.
No strict criteria exist as to when anticonvulsant withdrawal is appropriate. Patients who have been seizure free for at least 6 months may undergo consideration in discussion with their physician.
Surgical Treatment of Epilepsy
Epilepsy surgery is indicated for patients who have frequent, disabling seizures despite adequate trials of 2 or more anticonvulsants. Video EEG should be used before surgical referral to qualify events, assess severity, and aid in localization. Surgical procedures include temporal lobectomy, extratemporal resections, corpus callosotomy, placement of a vagus nerve stimulator, hemispherectomy, and multiple subpial transection.
Modification of Activity
All persons with uncontrolled seizures must be advised to refrain from high-risk activities that put themselves or others in danger in the event of a seizure. These activities include, but are not limited to, the following:
Operating a motor vehicle
Operating a stove or other dangerous machinery
Working at heights
Swimming in open/large bodies of water alone
Clinicians should document in writing that they have advised the patient not to operate a motor vehicle or dangerous machinery or to perform activities that would put the patient or others at risk of injury from a seizure. Persons with uncontrolled epilepsy should be advised to contact the appropriate state agency regarding driving regulations. Some states require physician reporting of drivers who experience seizures.
These activity restrictions should be reviewed in detail (and documented in the medical record) with the patient, family, and/or caregivers.
Refer the patient to an epilepsy specialist if the patient has seizures despite previous trials with 2 or 3 anticonvulsants. Consultation with such a specialist is indicated if the patient is a possible candidate for epilepsy surgery.
Jeffrey S. FDA Okays Vigabatrin as Add-on for Seizures in Children. Available at http://www.medscape.com/viewarticle/813666. Accessed: November 2, 2013.
Janszky J, Foqarasi A, Mafalova V. Unilateral hand automatisms in temporal lobe epilepsy. Seizure. 2006. 15(6):393-396. [Medline].
Kotagal P, Arunkumar G, Hammel J, Mascha E. Complex partial seizures of frontal lobe onset statistical analysis of ictal semiology. Seizure. 2003. 12(5):268-81. [Medline].
Loddenkemper T, Kotagal P. Lateralizing sings during seizures in focal epilepsy. Epilepsy and Behavior. 2005. 7:1-17. [Medline].
Horvath R, Kalmar Z, Feher N, Fogarasi A, Gyimesi C, Janszky J. Brain lateralization and seizure semiology: ictal clinical lateralizing signs. Ideggyogy Sz. Jully 2008. 61 (7-8):231-237. [Medline].
King MA, Newton MR, Jackson GD, et al. Epileptology of the first-seizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients. Lancet. 1998. 352(9133):1007-11. [Medline].
Knake S, Triantafyllou C, Wald LL, et al. 3T phased array MRI improves the presurgical evaluation in focal epilepsies: a prospective study. Neurology. 2005. 65(7):1026-1031. [Medline].
Arunkumar G, Morris H. Epilepsy update: new medical and surgical treatment options. Cleve Clin J Med. 1998. 65(10):527-32, 534-7. [Medline].
Browne TR. Pharmacokinetics of antiepileptic drugs. Neurology. 1998. 51(5 suppl 4):S2-7. [Medline].
Consensus Committee. Consensus statements: medical management of epilepsy. Neurology. 1998. 51(5 suppl 4):S39-43. [Medline].
Feely M. Fortnightly review: drug treatment of epilepsy. BMJ. 1999. 318(7176):106-9. [Medline].
French J, Smith M, Faught E, Brown L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 1999 May 12. 52(8):1540-5. [Medline].
French JA, Pedley TA. Clinical practice. Initial management of epilepsy. N Engl J Med. 2008 Jul 10. 359(2):166-76. [Medline].
Koepp MJ, Woermann FG. Imaging structure and function in refractory focal epilepsy. Lancet Neurol. 2005. 4(1):42-53. [Medline].
Levy RH, Mattson RH, Meldrum BS. Antiepileptic Drugs. 4th ed. New York, NY: Raven; 1995.
Mattson RH. Medical management of epilepsy in adults. Neurology. 1998. 51(5 suppl 4):S15-20. [Medline].
Pellock JM. Treatment of seizures and epilepsy in children and adolescents. Neurology. 1998. 51(5 Suppl 4):S8-14. [Medline].
Lee KH, Meador KJ, Park YD, et al. Pathophysiology of altered consciousness during seizures: subtraction SPECT study. Neurology. 2002. 59(6):841-6. [Medline].
Cascino GD. Temporal Lobe Epilepsy is a progressive Neurologic Disorder: time means Neurons!. Neurology. 2009. 72:1718-1719. [Medline].
Rocca WA, Sharbrough FW, Hauser WA, et al. Risk factors for complex partial seizures: a population-based case-control study. Ann Neurol. 1987 Jan. 21(1):22-31. [Medline].
Annegers JF. The epidemiology of epilepsy. Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice. Baltimore, Md: Williams & Wilkins; 1997. 165-2.
Cockerell OC. The mortality of epilepsy. Curr Opin Neurol. 1996. 9(2):93-6. [Medline].
Leestma JE, Walczak T, Hughes JR, et al. A prospective study on sudden unexpected death in epilepsy. Ann Neurol. 1989. 26(2):195-203. [Medline].
Luders H, Acharya J, Baugmgartner C, Benbadis S et al. Semiological seizure classification. Epilepsia. Sept 1998. 39 (9):1006-13. [Medline].
Noachtar S, Peters AS. Semiology of epileptic seizures: a critical review. Epilepsy Behavior. Mary 2009. 15(1):2-9. [Medline].
Pazzaglia P, D'Alessandro R, Lozito A, Lugaresi E. Classification of partial epilepsies according to the symptomatology of seizures: practical value and prognostic implications. Epilepsia. 1982 Jun. 23(3):343-50. [Medline].
Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia. 1998. 39(suppl 7):S3-7. [Medline].
Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology. 2005. 64(11):1874-8. [Medline].
Harden CL, Pennell PB, Hauser WA. Practice Parameter Update: Management Issues for women with epilepsy - focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding. Neurology. July 2009. 73 (2):142-149. [Medline].
Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006 Aug 8. 67(3):407-12. [Medline].
Morrell MJ. Guidelines for the care of women with epilepsy. Neurology. 1998. 51(5 suppl 4):S21-7. [Medline].
Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs [editorial]. Neurology. 1991 Jul. 41(7):961-4. [Medline].
American Academy of Neurology. Practice parameter: a guideline for discontinuing antiepileptic drugs in seizure-free patients--summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1996 Aug. 47(2):600-2. [Medline].
Benbadis SR. Epileptic Seizures and Syndromes. Neurologic Clinics. May 2001. 19 (2):[Medline].
Benbadis SR, Tatum WO. Advances in the Treatment of Epilepsy. American Family Physician. July 2001. 64 (1):91-98. [Medline].